These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33022750)

  • 1. Impact of KRAS status on tumor response and survival after neoadjuvant treatment of locally advanced rectal cancer.
    Zhou P; Goffredo P; Ginader T; Thompson D; Hrabe J; Gribovskaja-Rupp I; Kapadia M; Hassan I
    J Surg Oncol; 2021 Jan; 123(1):278-285. PubMed ID: 33022750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KRAS and Combined KRAS/TP53 Mutations in Locally Advanced Rectal Cancer are Independently Associated with Decreased Response to Neoadjuvant Therapy.
    Chow OS; Kuk D; Keskin M; Smith JJ; Camacho N; Pelossof R; Chen CT; Chen Z; Avila K; Weiser MR; Berger MF; Patil S; Bergsland E; Garcia-Aguilar J
    Ann Surg Oncol; 2016 Aug; 23(8):2548-55. PubMed ID: 27020587
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjuvant Chemotherapy Is Associated With Improved Overall Survival in Locally Advanced Rectal Cancer After Achievement of a Pathologic Complete Response to Chemoradiation.
    Shahab D; Gabriel E; Attwood K; Ma WW; Francescutti V; Nurkin S; Boland PM
    Clin Colorectal Cancer; 2017 Dec; 16(4):300-307. PubMed ID: 28420585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic role of the LCS6 KRAS variant in locally advanced rectal cancer: results of the EXPERT-C trial.
    Sclafani F; Chau I; Cunningham D; Peckitt C; Lampis A; Hahne JC; Braconi C; Tabernero J; Glimelius B; Cervantes A; Begum R; Gonzalez De Castro D; Hulkki Wilson S; Eltahir Z; Wotherspoon A; Tait D; Brown G; Oates J; Valeri N
    Ann Oncol; 2015 Sep; 26(9):1936-1941. PubMed ID: 26162609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of KRAS mutation as predictor of pathologic response after neoadjuvant chemoradiation therapy for rectal cancer.
    Martellucci J; Alemanno G; Castiglione F; Bergamini C; Valeri A
    Updates Surg; 2015 Mar; 67(1):47-53. PubMed ID: 25702261
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Implications of Pathological Response to Neoadjuvant Chemoradiation in Pathologic Stage III Rectal Cancer.
    Karagkounis G; Thai L; Mace AG; Wiland H; Pai RK; Steele SR; Church JM; Kalady MF
    Ann Surg; 2019 Jun; 269(6):1117-1123. PubMed ID: 31082910
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Significance of Neoadjuvant Rectal Score and Indication for Postoperative Adjuvant Therapy in Rectal Cancer Patients After Neoadjuvant Chemoradiotherapy.
    Maeda K; Shibutani M; Tachimori A; Nishii T; Aomatsu N; Fukuoka T; Nagahara H; Otani H; Inoue T; Ohira M
    In Vivo; 2020; 34(1):283-289. PubMed ID: 31882490
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant rectal score as individual-level surrogate for disease-free survival in rectal cancer in the CAO/ARO/AIO-04 randomized phase III trial.
    Fokas E; Fietkau R; Hartmann A; Hohenberger W; Grützmann R; Ghadimi M; Liersch T; Ströbel P; Grabenbauer GG; Graeven U; Hofheinz RD; Köhne CH; Wittekind C; Sauer R; Kaufmann M; Hothorn T; Rödel C;
    Ann Oncol; 2018 Jul; 29(7):1521-1527. PubMed ID: 29718095
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Significance of Mucinous Histology on Pathologic Complete Response Rate Following Capecitabine-Based Neoadjuvant Chemoradiation in Rectal Cancer: a Comparative Study.
    Hosseini S; Nguyen N; Mohammadianpanah M; Mirzaei S; Bananzadeh AM
    J Gastrointest Cancer; 2019 Dec; 50(4):716-722. PubMed ID: 29984382
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Validation of the Neoadjuvant Rectal Cancer (NAR) Score for Prognostication Following Total Neoadjuvant Therapy (TNT) for Locally Advanced Rectal Cancer.
    Shah S; Asawa P; Abel S; Wegner RE
    J Gastrointest Cancer; 2023 Sep; 54(3):829-836. PubMed ID: 36253514
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ten-year survival after pathologic complete response in rectal adenocarcinoma.
    Sell NM; Qwaider YZ; Goldstone RN; Cauley CE; Cusack JC; Ricciardi R; Bordeianou LG; Berger DL; Kunitake H
    J Surg Oncol; 2021 Jan; 123(1):293-298. PubMed ID: 33022797
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Chemotherapy Improves Survival Following Resection of Locally Advanced Rectal Cancer with Pathologic Complete Response.
    Turner MC; Keenan JE; Rushing CN; Gulack BC; Nussbaum DP; Benrashid E; Hyslop T; Strickler JH; Mantyh CR; Migaly J
    J Gastrointest Surg; 2019 Aug; 23(8):1614-1622. PubMed ID: 30635829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The neutrophil to albumin ratio as a predictor of pathological complete response in rectal cancer patients following neoadjuvant chemoradiation.
    Tawfik B; Mokdad AA; Patel PM; Li HC; Huerta S
    Anticancer Drugs; 2016 Oct; 27(9):879-83. PubMed ID: 27434664
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiomics of MRI for pretreatment prediction of pathologic complete response, tumor regression grade, and neoadjuvant rectal score in patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation: an international multicenter study.
    Shaish H; Aukerman A; Vanguri R; Spinelli A; Armenta P; Jambawalikar S; Makkar J; Bentley-Hibbert S; Del Portillo A; Kiran R; Monti L; Bonifacio C; Kirienko M; Gardner KL; Schwartz L; Keller D
    Eur Radiol; 2020 Nov; 30(11):6263-6273. PubMed ID: 32500192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Elevated platelet count is a negative predictive and prognostic marker in locally advanced rectal cancer undergoing neoadjuvant chemoradiation: a retrospective multi-institutional study on 965 patients.
    Belluco C; Forlin M; Delrio P; Rega D; Degiuli M; Sofia S; Olivieri M; Pucciarelli S; Zuin M; De Manzoni G; Di Leo A; Scabini S; Zorcolo L; Restivo A
    BMC Cancer; 2018 Nov; 18(1):1094. PubMed ID: 30419864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGF61 polymorphism predicts complete pathologic response to cetuximab-based chemoradiation independent of KRAS status in locally advanced rectal cancer patients.
    Hu-Lieskovan S; Vallbohmer D; Zhang W; Yang D; Pohl A; Labonte MJ; Grimminger PP; Hölscher AH; Semrau R; Arnold D; Dellas K; Debucquoy A; Haustermans K; Machiels JP; Sempoux C; Rödel C; Bracko M; Velenik V; Lenz HJ
    Clin Cancer Res; 2011 Aug; 17(15):5161-9. PubMed ID: 21673069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumor Heterogeneity as a Predictor of Response to Neoadjuvant Chemotherapy in Locally Advanced Rectal Cancer.
    Greenbaum A; Martin DR; Bocklage T; Lee JH; Ness SA; Rajput A
    Clin Colorectal Cancer; 2019 Jun; 18(2):102-109. PubMed ID: 30935775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating disparities in delivery of neoadjuvant guideline-based chemoradiation for rectal cancer: A multicenter, propensity score-weighted cohort study.
    Lau LW; Kethman WC; Bingmer KE; Ofshteyn A; Steinhagen E; Charles R; Dietz D; Stein SL
    J Surg Oncol; 2021 Oct; 124(5):810-817. PubMed ID: 34159619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic significance of neoadjuvant rectal score in locally advanced rectal cancer after neoadjuvant chemoradiotherapy and construction of a prediction model.
    Sun Y; Zhang Y; Wu X; Lin H; Lu X; Huang Y; Xu Z; Huang S; Wang X; Chi P
    J Surg Oncol; 2018 Mar; 117(4):737-744. PubMed ID: 29228455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The neoadjuvant rectal score and a novel magnetic resonance imaging based neoadjuvant rectal score are stage independent predictors of long-term outcome in locally advanced rectal cancer.
    McMahon RK; O'Cathail SM; Nair H; Steele CW; Platt JJ; Digby M; McDonald AC; Horgan PG; Roxburgh CSD
    Colorectal Dis; 2023 Sep; 25(9):1783-1794. PubMed ID: 37485654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.